PPARβ/δ protects against experimental colitis through a ligand-independent mechanism

被引:40
作者
Hollingshead, Holly E.
Morimura, Keiichirou
Adachi, Masahiro
Kennett, Mary J.
Billin, Andrew N.
Willson, Timothy M.
Gonzalez, Frank J.
Peters, Jeffrey M.
机构
[1] Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA
[2] Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA
[3] Penn State Univ, Grad Program Biochem Microbiol & Mol Biol, University Pk, PA 16802 USA
[4] NCI, Lab Metab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA
[5] GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA
关键词
peroxisome proliferator-activated receptor (PPAR)beta/delta; colitis; inflammatory bowel disease;
D O I
10.1007/s10620-006-9644-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Peroxisome proliferator-activated receptors (PPARs) beta/delta and gamma have overlapping roles in the negative regulation of inflammatory response genes. Ligand activation of PPAR gamma protects against experimental colitis in mice. PPAR beta/delta can negatively regulate inflammation and is highly expressed in the epithelial cells of the colon, therefore PPAR beta/delta may also have a role in experimental colitis. In these studies, colitis was induced by dextran sodium sulfate (DSS) treatment in wild-type and PPAR beta/delta-null mice, with and without the PPAR beta/delta specific ligand GW0742. PPAR beta/delta-null mice exhibited increased sensitivity to DSS-induced colitis, as shown by marked differences in body weight loss, colon length, colonic morphology, myeloperoxidase activity and increased expression of mRNAs encoding the inflammatory markers interferon gamma, tumor necrosis factor-alpha, and interleukin-6 compared to similarly treated wild-type mice. Interestingly, these differences were not affected by ligand activation of PPAR beta/delta in either genotype. These studies demonstrate that PPAR beta/delta expression in the colonic epithelium inhibits inflammation and protects against DSS-induced colitis through a ligand-independent mechanism.
引用
收藏
页码:2912 / 2919
页数:8
相关论文
共 46 条
[1]   Peroxisome proliferator activated receptor γ in colonic epithelial cells protects against experimental inflammatory bowel disease [J].
Adachi, M. ;
Kurotani, R. ;
Morimura, K. ;
Shah, Y. ;
Sanford, M. ;
Madison, B. B. ;
Gumucio, D. L. ;
Marin, H. E. ;
Peters, J. M. ;
Young, H. A. ;
Gonzalez, F. J. .
GUT, 2006, 55 (08) :1104-1113
[2]   Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease [J].
Bassaganya-Riera, J ;
Reynolds, K ;
Martino-Catt, S ;
Cui, YZ ;
Hennighausen, L ;
Gonzalez, F ;
Rohrer, J ;
Benninghoff, AU ;
Hontecillas, R .
GASTROENTEROLOGY, 2004, 127 (03) :777-791
[3]  
BASSAGANYARIERA J, IN PRESS CLIN NUTR
[4]   The immunological and genetic basis of inflammatory bowel disease [J].
Bouma, G ;
Strober, W .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (07) :521-533
[5]   TRAF2 plays a dual role in NF-κB-dependent gene activation by mediating the TNF-induced activation of p38 MAPK and IκB kinase pathways [J].
Carpentier, I ;
Declercq, W ;
Malinin, NL ;
Wallach, D ;
Fiers, W ;
Beyaert, R .
FEBS LETTERS, 1998, 425 (02) :195-198
[6]   Nuclear receptors in macrophage biology: At the crossroads of lipid metabolism and inflammation [J].
Castrillo, A ;
Tontonoz, P .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 2004, 20 :455-480
[7]  
COOPER HS, 1993, LAB INVEST, V69, P238
[8]   Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-α) in the development of inflammatory bowel disease in mice [J].
Cuzzocrea, S ;
Di Paola, R ;
Mazzon, E ;
Genovese, T ;
Muià, C ;
Centorrino, T ;
Caputi, AP .
LABORATORY INVESTIGATION, 2004, 84 (12) :1643-1654
[9]   Emerging roles of PPARs in inflammation and immunity [J].
Daynes, RA ;
Jones, DC .
NATURE REVIEWS IMMUNOLOGY, 2002, 2 (10) :748-759
[10]   Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (BPARγ) heterodimer:: A basis for new therapeutic strategies [J].
Desreumaux, P ;
Dubuquoy, L ;
Nutten, S ;
Peuchmaur, M ;
Englaro, W ;
Schoonjans, K ;
Derijard, B ;
Desvergne, B ;
Wahli, W ;
Chambon, P ;
Leibowitz, MD ;
Colombel, JF ;
Auwerx, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (07) :827-838